Literature DB >> 26603371

Do patients on oral chemotherapy have sufficient knowledge for optimal adherence? A mixed methods study.

A Arber1, A Odelius1, P Williams2, A Lemanska1, S Faithfull1.   

Abstract

A new treatment paradigm has emerged with many patients now receiving oral chemotherapy (OC) as first-line treatment for cancer. Treatment with OC has resulted in reduced hospital costs, more autonomy for patients but with added responsibilities for patient self-management. Little is known about patient's knowledge following patient education to enable optimal adherence with OC. A mixed methods study was carried out using a self-report questionnaire to patients on OC for multiple myeloma (MM) followed by semi-structured interviews with patients at home. Analysis identifies high rates of adherence (92.2%) with OC for MM. However, statistically significant knowledge deficits were identified, which were related to patient ethnicity and to gender. There is the potential for non-intentional non-adherence with OC due to deficits in knowledge of OC. Support at home needs to include primary care practitioners such as GPs, practice nurses and pharmacists so that timely support is easily accessible especially in the early phase of treatment.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  haematopoietic; oral chemotherapy; patient information

Mesh:

Substances:

Year:  2015        PMID: 26603371     DOI: 10.1111/ecc.12413

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  5 in total

1.  High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany.

Authors:  Stefan Feiten; Geothy Chakupurakal; Hans Peter Feustel; Michael Maasberg; Burkhard Otremba; Peter Ehscheidt; Manfred Hensel; Richard Hansen; Rudolf Weide
Journal:  Support Care Cancer       Date:  2019-03-11       Impact factor: 3.603

2.  Adherence to immunomodulatory drugs in patients with multiple myeloma.

Authors:  Amélie Cransac; Serge Aho; Marie-Lorraine Chretien; Maurice Giroud; Denis Caillot; Mathieu Boulin
Journal:  PLoS One       Date:  2019-03-27       Impact factor: 3.240

3.  Fear, faith and finances: health literacy experiences of English and Swahili speaking women newly diagnosed with breast and cervical cancer.

Authors:  Dinah Kassaman; Tayreez Mushani; Peterson Kiraithe; Sharon Brownie; Margaret Barton-Burke
Journal:  Ecancermedicalscience       Date:  2022-01-27

4.  Exploring the perspectives of healthcare professionals in delivering optimal oncology medication education.

Authors:  Allison Lively; Laura V Minard; Samantha Scott; Heidi Deal; Tessa Lambourne; Jenn Giffin
Journal:  PLoS One       Date:  2020-02-12       Impact factor: 3.240

Review 5.  Patients with low activation level report limited possibilities to participate in cancer care.

Authors:  Bodil Westman; Karin Bergkvist; Andreas Karlsson Rosenblad; Lena Sharp; Mia Bergenmar
Journal:  Health Expect       Date:  2022-01-20       Impact factor: 3.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.